Sorry missed this post.
This chart is a good example. The SOC drugs have response rates of only 20% and 37% (source is the Oct 23 announcement). And this response rate is as a 1st line of treatment, and was sufficient for an FDA approval. CHM's drug has shown a 55% response rate, and longer median survival rates.
I hope this better explains why CHM is confident re accelerated approval. Replication of the previous results already shows improvement over the already FDA approved drugs.
Hopefully with the Phase 1B ttial happening as a 2 line of treatment, further improvement will be seen in response rates and survival. But this is still an unknown.
- Forums
- ASX - By Stock
- CHM
- Chimeric: Media Thread
Chimeric: Media Thread, page-599
-
- There are more pages in this discussion • 289 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
CHM (ASX) Chart |
Day chart unavailable
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online